HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
2025 · 2nd Quarter (Apr 1 - June 30)
BIOMARIN PHARMACEUTICAL INC.
Filed by BIOMARIN PHARMACEUTICAL INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- Not reported
- Expenses
- $270,000.00
- Registrant
- BIOMARIN PHARMACEUTICAL INC.
- Filing UUID
- c8536344-fcbc-4781-8fb4-6e16f2bae694
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Literal federal measure citations: H.R. 1, H.R. 946, H.R. 1509, S. 752, S. 1637, S. 1862
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.